Avalo Therapeutics's total assets for Q1 2026 were $99.89M, a decrease of -14.23% from the previous quarter. AVTX total liabilities were $31.57M for the fiscal quarter, a -5.52% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.